Published in Arch Ophthalmol on April 01, 1975
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med (1991) 1.95
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer (1997) 1.57
Action spectrum for retinal injury from near-ultraviolet radiation in the aphakic monkey. Am J Ophthalmol (1982) 1.56
A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med (1977) 1.51
Observations on Cogan's microcystic dystrophy of the corneal epithelium. Trans Am Ophthalmol Soc (1965) 1.35
The nature of retinal radiation damage: dependence on wavelength, power level and exposure time. Vision Res (1980) 1.33
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
Proliferation, differentiation, and cytogenetics of chronic leukemic B lymphocytes cultured with mitomycin-treated normal cells. Blood (1981) 1.25
Basic mechanisms underlying the production of photochemical lesions in the mammalian retina. Curr Eye Res (1984) 1.21
Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet (1984) 1.15
Periodic hematopoiesis in human cyclic neutropenia. J Clin Invest (1973) 1.15
Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev (2001) 1.14
Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol (1999) 1.13
Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet (1980) 1.12
Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol (1984) 1.11
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol (1987) 1.06
Congenital orbital teratoma. Arch Ophthalmol (1974) 1.06
The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol (1993) 1.03
Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol (1993) 1.02
Dysplastic naevi and cutaneous melanoma risk. Lancet (1983) 0.99
Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. J Immunol (1985) 0.98
CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells. Int J Cancer (2000) 0.98
HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest (1984) 0.97
Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol (1990) 0.97
Concanavalin A-mediated binding and sphering of human red blood cells by homologous monocytes. J Exp Med (1976) 0.96
Cytogenetic evidence for the clonal nature of Richter's syndrome. Blood (1981) 0.93
Chronic neutropenia. Medicine (Baltimore) (1979) 0.93
Effect of cytochalasin B on human monocyte binding and sphering of IgG-coated human erythrocytes. Blood (1977) 0.92
Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer (1993) 0.91
Malignant angioendotheliomatosis proliferans treated with doxorubicin. Arch Dermatol (1982) 0.91
Characterization of tenascin secreted by human melanoma cells. Cancer Res (1991) 0.91
Effects of topical tretinoin on dysplastic nevi. J Clin Oncol (1994) 0.91
Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol (1991) 0.90
A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol (1993) 0.89
Production of multiple cytokines by cultured human melanomas. Exp Dermatol (1993) 0.89
Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. J Immunol (1987) 0.89
Natural history of dysplastic nevi. J Am Acad Dermatol (1993) 0.89
Production of interleukin 1 activity by cultured human melanoma cells. Cancer Res (1989) 0.89
Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann Plast Surg (2001) 0.88
The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer (1985) 0.88
Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer (1994) 0.88
MR imaging of intracranial metastatic melanoma. J Comput Assist Tomogr (1987) 0.87
Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. J Immunol (1989) 0.87
Lack of association between intraocular melanoma and cutaneous dysplastic nevi. Am J Ophthalmol (1984) 0.84
Recognition and classification of clinically dysplastic nevi from photographs: a study of interobserver variation. Cancer Epidemiol Biomarkers Prev (1995) 0.83
Neoplastic progression and prognosis in melanoma. Semin Cutan Med Surg (1996) 0.82
Ischemic colitis associated with factor V Leiden mutation. Ann Intern Med (2000) 0.81
Topical chemotherapy of dysplastic melanocytic nevi with 5% fluorouracil. Arch Dermatol (1981) 0.81
Phenotypic characteristics of cells derived from precursors of human melanoma. Cancer Res (1983) 0.81
Experiences with Light Coagulation of Fundus Lesions. Trans Am Ophthalmol Soc (1959) 0.81
Patient and physician delay in melanoma diagnosis. J Am Acad Dermatol (1988) 0.81
Chromosome 9 deletion in sporadic and familial melanomas in vivo. Oncogene (1994) 0.81
Melanuria. Acta Cytol (1986) 0.80
Managing the dysplastic naevus syndrome. Lancet (1984) 0.80
Immunoassay for melanoma-associated proteoglycan in the sera of patients using monoclonal and polyclonal antibodies. Cancer Res (1984) 0.80
Changes in membrane markers and chromosome patterns in chronic T-cell leukemia. Clin Immunol Immunopathol (1979) 0.80
Increased levels of circulating HLA-DR antigen in sera of patients with acute lymphoblastoid leukemia. Leuk Res (1984) 0.79
Granulocyte-associated IgG in neutropenic disorders. Blood (1982) 0.79
Human cutaneous nevi transplanted onto nude mice: a model for the study of the lesional steps in tumor progression. Cancer Res (1986) 0.78
Loco-regional nodal relapse in melanoma. Surg Oncol (1992) 0.77
B lymphocyte expression of a recognition locus for human monocytes and macrophages. J Immunol (1978) 0.77
Levels of disialogangliosides in sera of melanoma patients monitored by sensitive thin-layer chromatography and immunostaining. J Natl Cancer Inst (1989) 0.77
Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors. Cancer Immunol Immunother (1998) 0.77
Observations on Cogan's microcystic dystrophy of the corneal epithelium. Am J Ophthalmol (1966) 0.77
Effects of laser radiation on the mammalian eye. Trans N Y Acad Sci (1966) 0.76
Human cyclic neutropenia: urinary colony-stimulating factor and erythropoietin levels. Blood (1974) 0.76
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. Invest New Drugs (1987) 0.75
Curable melanomas: seek, and ye shall find. J Gen Intern Med (1993) 0.75
Disseminated melanoma--is there a new standard therapy? N Engl J Med (1992) 0.75
Bilateral choroidal detachment and fluctuating proptosis secondary to bilateral dural arteriovenous fistulas treated with transcranial orbital decompression with resolution: report of a case. Trans Am Ophthalmol Soc (1975) 0.75
Dural arteriovenous fistula and spontaneous choroidal detachment: new cause of an old disease. Br J Ophthalmol (1978) 0.75
Melanoma and other skin neoplasms. Curr Opin Oncol (1995) 0.75
Human monocyte-lymphocyte interaction and its enhancement by levamisole. Clin Exp Immunol (1979) 0.75
A study of the comparative effects of ionizing radiation and aging on the mammalian lens of the eye. Health Phys (1967) 0.75
Biomicroscopic characteristics of the aqueous veins. Eye Ear Nose Throat Mon (1969) 0.75
On widths of margins in excision of primary malignant melanomas. Ethics of randomized trials of wide and narrow margins. Am J Dermatopathol (1984) 0.75
The Use of the Sanborn Electromanometer in the Study of Pharmacological Effects upon the Intraocular Pressure. Trans Am Ophthalmol Soc (1951) 0.75
For the record: the history of precursors to malignant melanoma. Arch Dermatol (1984) 0.75
Factor XII deficiency with systemic lupus erythematosus. Biological implications. Arthritis Rheum (1979) 0.75
Light coagulation. Va Med Mon (1918) (1968) 0.75
"Catalyst" symptoms in malignant melanoma. J Gen Intern Med (1987) 0.75
Radiation-induced chromatid breaks and DNA repair in blood lymphocytes of patients with dysplastic nevi and/or cutaneous melanoma. J Invest Dermatol (1997) 0.75
Neutrophil-releasing activity in plasma of normal human subjects injected with etiocholanolone (39904). Proc Soc Exp Biol Med (1977) 0.75
Functional consequence of variation in melanoma antigen expression. Cancer Immunol Immunother (1983) 0.75
Black cornea secondary to topical epinephrine. Am J Ophthalmol (1971) 0.75
Target blue nevus. Arch Dermatol (1983) 0.75
Gene therapy for melanoma in humans. Hematol Oncol Clin North Am (1998) 0.75
Opportunistic pathogens in the immunologically hyperresponsive host. Pneumocystic carinii infection in a patient with allergic bronchopulmonary aspergillosis. Am J Med (1973) 0.75
Description of Recession Forceps. Trans Am Ophthalmol Soc (1959) 0.75
On the definition of the aqueous veins. Am J Ophthalmol (1968) 0.75
Melanoma and other skin neoplasms. Commentary. Curr Opin Oncol (1994) 0.75